Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial

R Bulbulia, L Bowman, K Wallendszus, S Parish, J Armitage, R Peto, R Collins, Heart Protection Study Collaborative Group, Peter Sandercock

Research output: Contribution to journalArticlepeer-review

Abstract

Findings of large randomised trials have shown that lowering LDL cholesterol with statins reduces vascular morbidity and mortality rapidly, but limited evidence exists about the long-term efficacy and safety of statin treatment. The aim of the extended follow-up of the Heart Protection Study (HPS) is to assess long-term efficacy and safety of lowering LDL cholesterol with statins, and here we report cause-specific mortality and major morbidity in the in-trial and post-trial periods.
Original languageEnglish
Pages (from-to)2013-20
Number of pages8
JournalThe Lancet
Volume378
Issue number9808
DOIs
Publication statusPublished - 2011

Fingerprint

Dive into the research topics of 'Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial'. Together they form a unique fingerprint.

Cite this